Gerresheimer AG Announces Supervisory Board Change Reflecting Shareholder Structure Evolution

Gerresheimer AG has announced a significant change to its Supervisory Board with Klaus Rohrig appointed to replace Dr. Dorothea Wenzel until the next Annual General Meeting in June 2026. This strategic move reflects the evolving shareholder structure of the pharmaceutical packaging and medical device company, signaling potential shifts in governance priorities and strategic direction for the global healthcare solutions provider.

Klaus Rohrig, co-founder and Co-Chief Investment Officer of the Active Ownership Group, brings substantial financial and investment expertise to Gerresheimer's oversight body. His appointment represents a deliberate alignment of board composition with current ownership dynamics, a crucial consideration for publicly traded companies seeking to maintain investor confidence and strategic coherence. The transition demonstrates how major corporations must continuously adapt their governance structures to reflect changing stakeholder landscapes.

Beyond his general Supervisory Board responsibilities, Rohrig will also assume Dr. Wenzel's previous duties on the Audit Committee, positioning him to directly influence financial oversight and compliance functions. This dual role assignment ensures continuity in critical monitoring functions while introducing fresh perspectives to the company's financial governance. The Audit Committee plays a vital role in maintaining financial integrity and regulatory compliance for publicly listed companies like Gerresheimer.

Dr. Axel Herberg, Chairman of the Supervisory Board, acknowledged Dr. Wenzel's contributions, stating she made significant contributions to committee duties through her expertise and experience. Such transitions, when managed professionally, demonstrate mature corporate governance practices that balance continuity with necessary evolution. The pharmaceutical packaging industry faces increasing regulatory scrutiny and technological transformation, making experienced oversight particularly valuable.

The appointment sets the stage for the upcoming Annual General Meeting scheduled for June 3, 2026, where Rohrig will stand for formal election to the Supervisory Board. This meeting will see four shareholder representatives up for election on Gerresheimer's co-determined Supervisory Board, potentially representing a broader reshaping of the company's governance framework. The co-determination model, common in German corporations, balances shareholder and employee interests in corporate oversight.

Gerresheimer operates as a global partner for pharmaceutical, biotech, and cosmetic industries, offering comprehensive drug containment solutions and delivery systems. The company's extensive product portfolio includes digital therapy support solutions, medical devices, syringes, auto-injectors, inhalers, and various containment products. With over 40 production sites across 16 countries and approximately 13,600 employees globally, Gerresheimer maintains significant presence in healthcare markets worldwide. The company generated revenues around EUR 2.4 billion in 2024 following its integration with Bormioli Pharma, positioning it as a major player in pharmaceutical packaging and medical device sectors. Additional information about the company's operations and governance can be found at https://www.gerresheimer.com.

This board transition occurs amid increasing complexity in global healthcare supply chains and regulatory environments. Pharmaceutical packaging companies face growing demands for enhanced sustainability, digital integration, and patient safety features. Governance changes at major industry players like Gerresheimer can signal strategic shifts in how companies address these challenges while maintaining operational excellence and regulatory compliance across diverse international markets.